Evidence map›Paper›PMID 29768384›Full record

ArticleMedicine2018

Therapeutic experience of severe and recurrent secondary hyperparathyroidism in a patient on hemodialysis for 18 years: A case report.

Mingwen Zhu, Zongming Zhang, Fangcai Lin, Jieping Miao, Pei Wang, Chong Zhang, Hongwei Yu, Hai Deng, Zhuo Liu, Limin Liu and 8 more

Abstract readCase Reports
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mingwen ZhuDepartment of General Surgery Department of Nephrology Department of Nuclear Medicine, Beijing Electric Power Hospital, State Grid Corporation of China, Capital Medical University Department of General Surgery, The First Affiliated Hospital, School of Medicine, Tsinghua University, Beijing, China.
Zongming Zhang
Fangcai Lin
Jieping Miao
Pei Wang
Chong Zhang
Hongwei Yu
Hai Deng
Zhuo Liu
Limin Liu
Baijiang Wan
Haiyan Yang
Mengmeng Song
Yue Zhao
Nan Jiang
Zichao Zhang
Zhenya Zhang
Lijie Pan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFor patients with refractory secondary hyperparathyroidism (SHPT), parathyroidectomy (PTX) has received increasing attention. However, evidence-based medicine shows that there is still controversy regarding surgical methods, efficacy, and safety. We retrospectively analyzed the process of diagnosis and treatment in one patient with severe SHPT and long-term chronic renal failure (CRF), so as to further improve the therapeutic effect. CASE PRESENTATION: A 61-year-old female with SHPT and CRF manifested as no urine for 18 years, underwent PTX 4 times since September 2010, with satisfactory final recovery. The first operation involved resection of 3 parathyroid glands in the normal position; the second operation involved removal of an ectopic parathyroid gland, combined with parathyroid gland autotransplantation; the third operation was performed to resect suspected recurrent parathyroid gland; the fourth operation involved partial excision of the autotransplanted parathyroid glands.

conclusionAccurate preoperative localized diagnosis and optimal surgical approach play key roles in the prevention and treatment of SHPT; postoperative recurrence of SHPT caused by ectopic or autotransplanted parathyroid gland should receive more attention.

Indexed as

FemaleHumansHyperparathyroidism, SecondaryKidney Failure, ChronicMiddle AgedParathyroidectomyParathyroid GlandsRecurrenceRenal DialysisRetrospective StudiesTime FactorsTransplantation, Autologous

Identifiers

PMID29768384
PMCPMC5976323

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.